Minneapolis Clinical Trials
Liver Study
The purpose of this study is to evaluate the study medication, Lorlatinib in males and females with moderate to severe liver impairment.
8 nights
3 visits
Purpose: to evaluate the safety and tolerability of an investigational medication on people with liver impairment.
This study has 8 nights/ 9 day consecutive stay in-house at our St. Paul facility plus 1 outpatient visit.
This study has been reviewed by an independent ethics committee.
Reimbursement for study participation will be provided for time and travel of up to $2,750.
Call our direct recruitment line at 612-315-6490 or register your interest to discuss your eligibility today!
Transportation can be arranged to and from the clinic for screening, confinement and follow up visits.
Eligibility
Age: 18-75
BMI: 17.5-40 kg/m2
Medication: Stable medications for 7 days prior to admit
Smoking Status: You must abstain from the use of tobacco- or nicotine-containing products for 24 hours before dosing and until the end of confinement.
Compensation: Up to $2,750